Challenges and Opportunities for Defining Arrhythmogenic Substrates in Ventricular Arrhythmias

Dr. Jeffrey Winterfield presents “Challenges and Opportunities for Defining Arrhythmogenic Substrates in Ventricular Arrhythmias” on January 23, 2024 as part of the Cardiac Sciences Grand Rounds series. About the Speaker Dr. Jeffrey Winterfield is the Hank and Laurel Greer Chair and Professor of Medicine at the Medical University of South Carolina. He received his undergraduate degree from Amherst College in Massachusetts and medical degree with Honors from the University of Chicago Pritzker School of Medicine. He completed his internal medicine training at the University of Texas Southwestern Medical Center in Dallas where he also served as a Howard Hughes Medical Institute Postdoctoral Fellow in ion channel biophysics. After completing his internal medicine residency, he was selected for a highly competitive fellowship in cardiovascular medicine at the Brigham and Women's Hospital, part of Harvard Medical School, in Boston. Dr. Winterfield's developed his interests in catheter ablation of ventricular arrhythmias and the development of novel mapping and imaging techniques while working with Drs. Usha Tedrow and William Stevenson at the Brigham. In 2011, he took his first faculty position in the prestigious heart rhythm program at Loyola University Medical Center in Chicago where he remained for five years. During that time in Chicago, he published multiple papers and abstracts, participated as a principal investigator in clinical trials regarding complex rhythm management, and served as faculty in national and international meetings. In 2016, he was recruited to the Medical University of South Carolina (MUSC) for his expertise in catheter ablation of complex arrhythmias, particularly ventricular tachycardia (VT) and premature ventricular contractions (PVCs). In 2017, he was named Chief of the Cardiac Electrophysiology Section at MUSC. He has special expertise in catheter ablation of arrhythmias on the outside of the heart (epicardial VT) as well as experimental techniques in ablation with both industry and National Institutes of Health (NIH) funding. He has a particular interest in VT in patients with advanced heart disease including ischemic and non-ischemic cardiomyopathies.